Skip to content

US · DNTH · BIOTECHNOLOGY

Dianthus Therapeutics, Inc. (DNTH) intrinsic value and stock valuation

$84.55as of 2026-11-21 · Mkt cap 4.7B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dianthus Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DNTH with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from DNTH’s statements →

Dianthus Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10036 dianthustx.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$2.04M
20162025
Net income
-$-162.34M
20162025
Free cash flow
-$-129.27M
20162025
Total equity
$493.4M+27.9% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$2.04M$6.24M$2.83M$6.42M$1.48M
Operating income-$-177.93M-$-101.86M-$-48.17M-$-29.7M-$-13.09M
Net income-$-162.34M-$-84.97M-$-43.55M-$-28.48M-$-13.11M
EPSd-$-4.3M-$-2.55M-$-8.46M-$-7.59M-$-3.82M
Operating cash flow-$-129.06M-$-78.18M-$-36.86M-$-29.07M-$-59.53M
Capital expenditure-$-210K-$-100K-$-110K-$-140K-$-1.26M
Free cash flow-$-129.27M-$-78.28M-$-36.97M-$-29.21M-$-60.8M
Total assets$530.9M$374M$179.4M$83.1M$189.9M
Total debt$1.39M$1.49M$580K$790K$0.00
Net debt-$-49.7M-$-21.3M-$-131.74M-$-14.58M-$-131.65M
Total equity$493.4M$352.5M$168.9M$73.7M$172.7M
Cash and short-term investments$404.3M$275.2M$173.7M$75.5M$176.9M
Income statement
20252024202320222021
Revenue$2.04M$6.24M$2.83M$6.42M$1.48M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$2.04M$6.24M$2.83M$6.42M$1.48M
Research and development expenses$145.6M$83.1M$32.8M$29.4M$12.6M
Selling, general and administrative expenses$34.3M$25M$18.2M$6.74M$1.96M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$180M$108.1M$51M$36.1M$14.6M
Cost and expenses$180M$108.1M$51M$36.1M$14.6M
Interest income$16.1M$17.4M$4.76M$1.15M$100K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$430K$410K$350K$150K$2.02M
Ebitda-$-161.91M-$-84.56M-$-43.2M-$-28.33M-$-11.09M
Operating income-$-177.93M-$-101.86M-$-48.17M-$-29.7M-$-13.09M
Total other income/expenses, net$15.6M$16.9M$4.62M$1.23M-$-20K
Income before tax-$-162.34M-$-84.97M-$-43.55M-$-28.48M-$-13.11M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-162.34M-$-84.97M-$-43.55M-$-28.48M-$-13.11M
Weighted average shares outstanding$37.8M$33.3M$5.15M$3.75M$3.43M
Weighted average diluted shares outstanding$37.8M$33.3M$5.15M$3.75M$3.43M
Balance sheet
20252024202320222021
Cash and short-term investments$404.3M$275.2M$173.7M$75.5M$176.9M
Net receivables$100K$810K$480K$5.64M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$409.4M$280.9M$177.5M$82M$180.7M
Property, plant and equipment, net$1.63M$1.75M$800K$960K$7.46M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$110.1M$81.7M$0.00$0.00$1.78M
Total non-current assets$121.5M$93.1M$1.95M$1.08M$9.24M
Total assets$530.9M$374M$179.4M$83.1M$189.9M
Accounts payable$9.72M$4.58M$2.61M$1.17M$3.04M
Short-term debt$370K$320K$420K$350K$0.00
Deferred revenue$1.19M$480K$100K$100K$0.00
Total current liabilities$30.7M$18.5M$9.63M$8.22M$10.9M
Long-term debt$1.02M$1.17M$170K$440K$0.00
Deferred revenue, non-current$5.77M$1.91M$740K$790K$0.00
Total non-current liabilities$6.79M$3.08M$900K$1.23M$6.4M
Capital lease obligations$370K$1.49M$580K$790K$0.00
Total liabilities$37.5M$21.5M$10.5M$9.45M$17.3M
Common stock$40K$30K$10K$0.00$60K
Retained earnings-$-336.73M-$-174.39M-$-89.42M-$-45.87M-$-325.57M
Accumulated other comprehensive income (loss)$490K$110K$50K-$-160K-$-30K
Total equity$493.4M$352.5M$168.9M$73.7M$172.7M
Total investments$463.3M$334.2M$41.4M$60.1M$47.1M
Total debt$1.39M$1.49M$580K$790K$0.00
Net debt-$-49.7M-$-21.3M-$-131.74M-$-14.58M-$-131.65M
Cash flow statement
20252024202320222021
Net income-$-162.34M-$-84.97M-$-43.55M-$-28.48M-$-71.14M
Depreciation and amortization$430K$410K$350K$150K$2.02M
Stock-based compensation$22.8M$12.9M$2.9M$1.52M$0.00
Change in working capital$16.7M-$-350K$4.86M-$-1.65M-$-1.53M
Accounts receivable$760K$0.00$5.16M-$-4.16M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$11.3M$8.19M$660K$2.28M-$-720K
Net cash provided by operating activities-$-129.06M-$-78.18M-$-36.86M-$-29.07M-$-59.53M
Investments in property, plant and equipment-$-210K-$-100K-$-110K-$-140K-$-1.26M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-122.83M-$-286.81M$20.3M-$-59.82M$43.4M
Common stock issued$280.1M$269.2M$72M$0.00$89.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$280.1M$255.6M$133.6M$96.7M$89.6M
Net change in cash$28.2M-$-109.37M$117M$7.79M$73.5M
Cash at end of period$51.3M$23M$132.4M$15.4M$131.7M
Operating cash flow-$-129.06M-$-78.18M-$-36.86M-$-29.07M-$-59.53M
Capital expenditure-$-210K-$-100K-$-110K-$-140K-$-1.26M
Free cash flow-$-129.27M-$-78.28M-$-36.97M-$-29.21M-$-60.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dianthus Therapeutics, Inc.

        Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

        CEO
        Marino Garcia
        Employees
        92
        Beta
        0.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Dianthus Therapeutics, Inc. (DNTH)?

        Dianthus Therapeutics, Inc. (DNTH) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is DNTH undervalued?

        DNTH trades at a price of $84.55 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.